ArticleScientific reports2025
Prognostic value of preoperative serum ferritin in cholangiocarcinoma patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cholangiocarcinoma is a common malignant tumor that seriously endangers physical and mental health. Elevated serum ferritin levels are correlated with reduced survival and increased recurrence rates in various cancers. The present study aimed to evaluate the potential of serum ferritin as a prognostic biomarker in cholangiocarcinoma. Immunoassay was used to detect ferritin protein in the serum of 120 cholangiocarcinoma patients and to compare the diagnostic utility of the conventional tumour markers CEA, CA19-9 and CA125. The median DFS for all patients was 420 days (range, 1.0-51.8 months). Median survival was 991 days (range, 2.1-51.8 months) and 361 days (range, 1.0-51.8 months) in the low- and high-ferritin level groups, respectively (P < 0.001). Patients with cholangiocarcinoma with low ferritin expression (≤ 196.5 ng/ml) had significantly higher disease-free survival than those with high ferritin expression (> 196.5 ng/ml). The findings of multivariate analyses showed serum ferritin (P = 0.001), CA19-9 (P = 0.037), Tbil (P = 0.017), and Ki67 (P = 0.008), lymph node metastasis (P = 0.040) and no lymph node dissection (P<0.001) were considered as independent factors affecting the prognosis. Ferritin levels had statistically significant relationship between patient's CA19-9 level, Vascular invasion, CD34/31 expression and Postoperative adjuvant therapy (P < 0.05). These results indicate that serum ferritin is prognostically associated with patients with cholangiocarcinoma and may serve as a valuable prognostic biomarker for patients with cholangiocarcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.